These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 22189665)

  • 1. Secondary hyperparathyroidism: benign bystander or culpable contributor to adverse health outcomes?
    Peiris AN; Youssef D; Grant WB
    South Med J; 2012 Jan; 105(1):36-42. PubMed ID: 22189665
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
    Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
    Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
    Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB
    Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The consequences of uncontrolled secondary hyperparathyroidism and its treatment in chronic kidney disease.
    Goodman WG
    Semin Dial; 2004; 17(3):209-16. PubMed ID: 15144547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Challenges in the therapy of secondary hyperparathyroidism.
    Wood C; González EA; Martin KJ
    Ther Apher Dial; 2005 Feb; 9(1):4-8. PubMed ID: 15828898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Increase of PTH in post-menopausal osteoporosis].
    Cerdà D; Peris P; Monegal A; Albaladejo C; Martínez de Osaba MJ; Surís X; Guañabens N
    Rev Clin Esp; 2011; 211(7):338-43. PubMed ID: 21596374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis of parathyroid hyperplasia in renal failure.
    Cozzolino M; Brancaccio D; Gallieni M; Galassi A; Slatopolsky E; Dusso A
    J Nephrol; 2005; 18(1):5-8. PubMed ID: 15772917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism.
    Henley C; Colloton M; Cattley RC; Shatzen E; Towler DA; Lacey D; Martin D
    Nephrol Dial Transplant; 2005 Jul; 20(7):1370-7. PubMed ID: 15855208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paricalcitol, a new agent for the management of secondary hyperparathyroidism in patients undergoing chronic renal dialysis.
    Goldenberg MM
    Clin Ther; 1999 Mar; 21(3):432-41. PubMed ID: 10321413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.
    Brown AJ; Slatopolsky E
    Nat Clin Pract Endocrinol Metab; 2007 Feb; 3(2):134-44. PubMed ID: 17237840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo studies of parathyroid gland function in secondary hyperparathyroidism.
    Salusky IB; Goodman WG
    Adv Nephrol Necker Hosp; 1996; 25():289-302. PubMed ID: 8717632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increases in parathyroid hormone (PTH) after gastric bypass surgery appear to be of a secondary nature.
    Jin J; Robinson AV; Hallowell PT; Jasper JJ; Stellato TA; Wilhem SM
    Surgery; 2007 Dec; 142(6):914-20; discussion 914-20. PubMed ID: 18063076
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Laboratory screening for hyperparathyroidism.
    Younes NA; Shafagoj Y; Khatib F; Ababneh M
    Clin Chim Acta; 2005 Mar; 353(1-2):1-12. PubMed ID: 15698586
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors modulating cytosolic calcium. Role in lipid metabolism and cardiovascular morbidity and mortality in peritoneal dialysis patients.
    Gadallah MF; el-Shahawy M; Andrews G; Ibrahim M; Ramdeen G; Hanna D; Gorospe W; Morkos A; Abbassian M; Moles K
    Adv Perit Dial; 2001; 17():29-36. PubMed ID: 11510292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parathyroid hormone as a mortality predictor in frail aged inpatients.
    Bjorkman M; Sorva A; Tilvis R
    Gerontology; 2009; 55(6):601-6. PubMed ID: 19752529
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary hyperparathyroidism promotes the acute phase response -- a rationale for supplemental vitamin D in prevention of vascular events in the elderly.
    McCarty MF
    Med Hypotheses; 2005; 64(5):1022-6. PubMed ID: 15780504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.